Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
Executive Summary
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.